CytomX Therapeutics, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$663K
↓-98.3% -$37Mvs FY2024 (Q4)
Gross Profit
$663K
↓-98.3% -$37Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $663K | $38M |
| COGS | $0 | $0 |
| Gross Profit | $663K | $38M |
| R&D | $21M | $15M |
| SG&A | $0 | $0 |
| D&A | $100K | $500K |
| Other OpEx | $0 | $5M |
| Operating Income | $0 | $18M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $18M |
| Tax | $0 | $62K |
| Net Income | $0 | $18M |
QuarterCharts · SEC EDGAR data · CTMX · Comparing FY2025 (Q4) vs FY2024 (Q4)